Innoviva Statistics
Total Valuation
Innoviva has a market cap or net worth of $1.11 billion. The enterprise value is $1.13 billion.
Important Dates
The next estimated earnings date is Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Innoviva has 63.02 million shares outstanding. The number of shares has increased by 14.14% in one year.
| Current Share Class | 63.02M |
| Shares Outstanding | 63.02M |
| Shares Change (YoY) | +14.14% |
| Shares Change (QoQ) | +34.67% |
| Owned by Insiders (%) | 0.95% |
| Owned by Institutions (%) | 112.91% |
| Float | 57.65M |
Valuation Ratios
The trailing PE ratio is 32.96 and the forward PE ratio is 8.76. Innoviva's PEG ratio is 0.25.
| PE Ratio | 32.96 |
| Forward PE | 8.76 |
| PS Ratio | 2.98 |
| Forward PS | 2.74 |
| PB Ratio | 1.55 |
| P/TBV Ratio | 2.21 |
| P/FCF Ratio | 5.53 |
| P/OCF Ratio | 5.52 |
| PEG Ratio | 0.25 |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 5.45, with an EV/FCF ratio of 5.62.
| EV / Earnings | 29.16 |
| EV / Sales | 3.04 |
| EV / EBITDA | 5.45 |
| EV / EBIT | 6.24 |
| EV / FCF | 5.62 |
Financial Position
The company has a current ratio of 2.64, with a Debt / Equity ratio of 0.72.
| Current Ratio | 2.64 |
| Quick Ratio | 2.38 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 2.49 |
| Debt / FCF | 2.58 |
| Interest Coverage | 9.07 |
Financial Efficiency
Return on equity (ROE) is 5.60% and return on invested capital (ROIC) is 9.34%.
| Return on Equity (ROE) | 5.60% |
| Return on Assets (ROA) | 8.83% |
| Return on Invested Capital (ROIC) | 9.34% |
| Return on Capital Employed (ROCE) | 16.62% |
| Revenue Per Employee | $2.92M |
| Profits Per Employee | $304,323 |
| Employee Count | 127 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 1.22 |
Taxes
In the past 12 months, Innoviva has paid $26.90 million in taxes.
| Income Tax | 26.90M |
| Effective Tax Rate | 41.04% |
Stock Price Statistics
The stock price has decreased by -11.84% in the last 52 weeks. The beta is 0.41, so Innoviva's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | -11.84% |
| 50-Day Moving Average | 18.78 |
| 200-Day Moving Average | 18.81 |
| Relative Strength Index (RSI) | 44.17 |
| Average Volume (20 Days) | 767,696 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Innoviva had revenue of $370.23 million and earned $38.65 million in profits. Earnings per share was $0.53.
| Revenue | 370.23M |
| Gross Profit | 318.19M |
| Operating Income | 180.69M |
| Pretax Income | 65.55M |
| Net Income | 38.65M |
| EBITDA | 206.86M |
| EBIT | 180.69M |
| Earnings Per Share (EPS) | $0.53 |
Full Income Statement Balance Sheet
The company has $497.73 million in cash and $517.32 million in debt, giving a net cash position of -$19.59 million or -$0.31 per share.
| Cash & Cash Equivalents | 497.73M |
| Total Debt | 517.32M |
| Net Cash | -19.59M |
| Net Cash Per Share | -$0.31 |
| Equity (Book Value) | 714.82M |
| Book Value Per Share | 11.34 |
| Working Capital | 405.22M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was $200.62 million and capital expenditures -$270,000, giving a free cash flow of $200.35 million.
| Operating Cash Flow | 200.62M |
| Capital Expenditures | -270,000 |
| Free Cash Flow | 200.35M |
| FCF Per Share | $3.18 |
Full Cash Flow Statement Margins
Gross margin is 85.94%, with operating and profit margins of 48.81% and 10.44%.
| Gross Margin | 85.94% |
| Operating Margin | 48.81% |
| Pretax Margin | 17.71% |
| Profit Margin | 10.44% |
| EBITDA Margin | 55.87% |
| EBIT Margin | 48.81% |
| FCF Margin | 54.11% |
Dividends & Yields
Innoviva does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.14% |
| Shareholder Yield | -14.14% |
| Earnings Yield | 3.49% |
| FCF Yield | 18.09% |
Dividend Details Analyst Forecast
The average price target for Innoviva is $35.60, which is 102.62% higher than the current price. The consensus rating is "Buy".
| Price Target | $35.60 |
| Price Target Difference | 102.62% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 12.17% |
| EPS Growth Forecast (5Y) | 61.00% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Innoviva has an Altman Z-Score of 2.24 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.24 |
| Piotroski F-Score | 6 |